Achaogen Inc (NASDAQ:AKAO), which is a clinical-stage biopharmaceutical company, has put on board a new member of staff. Effective July 5, 2016, Mr. Tobin Schilke will take the role of a Chief Financial Officer and will be answerable to Kenneth Hillan, the company’s Chief Executive Officer.
The 41year old Schilke has been serving as Chief Financial Officer and Company Director of Roche Products Limited in the United Kingdom for the last 13 years hence; he has a wealth of experience. He has also served as a Director of Genentech’s Commercial Finance BioOncology Business Unit.
Some of the critical roles that Schilke played in both companies included financial planning, procurement, legal & financial compliance, supply chain among others.
Speaking about the new appointment, Hillan has confirmed that Schilke will be an asset to clinical-stage Biopharmaceutical Company and its team given that he is a proven executive who has shaped and led other flourishing teams. The company will have so much to gain from his experience and expertise and apparently the appointment comes at a time when the company is entering a critical growth stage.
With a Bachelor of Science degree in Chemical Engineering from Lafayette College in Easton and a Masters of Science degree, he is expected to give Achaogen team a new look altogether. In any case, he also has a Masters of Business Administration degree from New York, which will come in handy in his day to day running of activities.
Commenting on his appointment, Mr. Schilke expressed gratitude and is very enthusiastic about being able to propel the company to the next level. His desire is to lead the company into achieving its strategic objectives and financial goals which will in return address the urgent need for new treatment options.
Mr. Schilke is receiving a handsome annual pay of $315,000. He will also be entitled to a discretionary cash bonus for the fiscal year. In his first 30 days of employment, the company will pay him a $35,000 sign-on bonus. Any relocation expenses will be reimbursed at the tune of up to $60,000.
